Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan. It is also developing SNP-810 is in phase II clinical trial for use in pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetaminophen poisoning, and SNP-830 and SNP-840, which in pre-clinical trial are used as hepatotoxicity-free analgesic medicines in the United States. Sinew Pharma Inc. was founded in 2014 and is based in Taipei City, Taiwan.
Frequently asked questions
What sector does Sinew Pharma Inc. (6634) operate in?
Sinew Pharma Inc. belongs to the Other sector and operates in the Biotechnology industry.
What is Sinew Pharma Inc. (6634) current stock price?
As of the latest data, Sinew Pharma Inc. stock price is NT$55.50, with a previous close of NT$55.50.
What is Sinew Pharma Inc. (6634) current market capitalization?
Sinew Pharma Inc. market cap is approximately 3.96 billion.
What is Sinew Pharma Inc. (6634) Earnings Per Share (EPS)?
The trailing EPS is -NT$1.74.
Does Sinew Pharma Inc. (6634) pay dividends?
No. Sinew Pharma Inc. does not pay a dividend.
What is Sinew Pharma Inc. (6634) beta (volatility) score?
Sinew Pharma Inc. has a beta of 0.522, indicating lower volatility than the overall market.
